XOMA Corporation (XOMA) |
|
19.78 -0.39 (-1.93%)
|
09-20 00:46 |
|
Open: |
20.47 |
Pre. Close: |
20.17 |
|
High:
|
21.14 |
Low:
|
19.77 |
|
Volume:
|
106,148 |
Market Cap:
|
218M |
|
|
|
|
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 10 full-time employees. The firm focuses on the discovery and development of monoclonal antibody-based therapeutics. The company has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
21.172 - 21.32 |
21.32 - 21.433 |
|
Low:
|
19.399 - 19.591 |
19.591 - 19.739 |
|
Close:
|
19.516 - 19.774 |
19.774 - 19.972 |
|
Technical analysis |
as of: 2020-09-18 4:37:17 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 25.17 One year: 29.40 |
| Support: |
Support1: 19.33  Support2: 17.96 |
| Resistance: |
Resistance1: 21.55 Resistance2: 25.17 |
| Pivot: |
19.65 |
| Moving Average: |
MA(5): 20.45 MA(20): 19.67
MA(100): 20.18 MA(250): 21.56 |
| MACD: |
MACD(12,26): 0.39 Signal(9): 0.34 |
| Stochastic oscillator: |
%K(14,3): 61.93 %D(3): 70.62 |
| RSI: |
RSI(14): 52.79 |
| 52-week: |
High: 28.85 Low: 14.14 Change(%): 3.9 |
| Average Vol(K): |
3-Month: 5437 10-Days: 3994 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.XOMA has closed below upper band by 44.9%. Bollinger Bands are 38.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 10 Sep 2020
Is XOMA (NASDAQ:XOMA) Using Too Much Debt? - Simply Wall St
Wed, 02 Sep 2020
XOMA to Present at Upcoming Investor Conferences - Yahoo Finance
Mon, 31 Aug 2020
Botulism Illness Market Entry Strategies, Countermeasures, Economic Impact And Quantum Sensors Marketing Channels To 2027 | Microbiotix, XOMA Corporation, Molecular Targeting Technologies, AlphaVax, Morphotek - The Daily Chronicle
Fri, 21 Aug 2020
Biodefense Market Sets the Table for Continued Growth | Cleveland BioLabs, Xoma, Bavarian Nordic - The Daily Chronicle
Thu, 13 Aug 2020
What Type Of Shareholders Make Up XOMA Corporation’s (NASDAQ:XOMA) Share Registry? - Simply Wall St
Thu, 06 Aug 2020
XOMA Reports Second Quarter 2020 Financial Results Nasdaq:XOMA - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
11 |
| Shares Float (M) |
6 |
|
% Held by Insiders
|
5.54 |
|
% Held by Institutions
|
59.08 |
|
Shares Short (K)
|
690 |
|
Shares Short P. Month (K)
|
701 |
Stock Financials |
|
EPS
|
-0.990 |
|
EPS Est This Year
|
-2.930 |
|
EPS Est Next Year
|
-1.320 |
|
Book Value (p.s.)
|
3.480 |
|
Profit Margin
|
-89.63 |
|
Operating Margin
|
-85.28 |
|
Return on Assets (ttm)
|
-6.8 |
|
Return on Equity (ttm)
|
-31.8 |
|
Qtrly Rev. Growth
|
-53.8 |
|
Gross Profit (p.s.)
|
1.554 |
|
Sales Per Share
|
0.956 |
|
EBITDA (p.s.)
|
-0.812 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-6 |
|
Levered Free Cash Flow (M)
|
-17 |
Stock Valuations |
|
PE Ratio
|
-19.98 |
|
PEG Ratio
|
|
|
Price to Book value
|
5.68 |
|
Price to Sales
|
20.70 |
|
Price to Cash Flow
|
-39.63 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
